HRP20100672T1 - Hcv ns5b inhibitori - Google Patents
Hcv ns5b inhibitori Download PDFInfo
- Publication number
- HRP20100672T1 HRP20100672T1 HR20100672T HRP20100672T HRP20100672T1 HR P20100672 T1 HRP20100672 T1 HR P20100672T1 HR 20100672 T HR20100672 T HR 20100672T HR P20100672 T HRP20100672 T HR P20100672T HR P20100672 T1 HRP20100672 T1 HR P20100672T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclohexyl
- benzazepine
- carboxylic acid
- indol
- methyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 10
- 101710112514 Host translation inhibitor 5b Proteins 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 claims abstract 23
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 239000000203 mixture Substances 0.000 claims abstract 5
- -1 N-alkylpiperazinyl Chemical group 0.000 claims 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000004702 methyl esters Chemical class 0.000 claims 13
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 239000012268 protein inhibitor Substances 0.000 claims 5
- 229940121649 protein inhibitor Drugs 0.000 claims 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- 108010036941 Cyclosporins Proteins 0.000 claims 2
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Spoj formule Inaznacen time sto: R1 je CO2R5 ili CONR6R7;R2 je furanil, pirolil, tienil, pirazolil, oksazolil, tiazolil, izoksazolil, izotiazolil, oksadiazolil, triazolil, ili tetrazolil, i supstituiran je s 0-2 supstituenta izabranih izmedu okso, amino, alkilamino, dialkilamino, alkil, (cikloalkil)alkil, hidroksialkil, (tetrahidrofuranil)alkil, (tetrahidropiranil)alkil, (CO2R5)alkil, (CON(R5)2)alkil, (COR9)alkil, (alkilsulfonil)alkil, i ((R9)alkil)CON(R5);R3 je C5-7cikloalkil; R4 je vodik, halo, hidroksi, alkil, ili alkoksi; R5 je vodik, alkil, ili cikloalkil; R6 je vodik, alkil, cikloalkil, alkoksi, ili SO2R8;R7 je vodik , alkil, ili cikloalkil; ili NR6R7 uzeti zajedno su pirolidinil, piperidinil, piperazinil, N-alkilpiperazinil, homomorfolinil, homopiperidinil, morfolinil, ili tiomorfolinil; R8 je alkil, haloalkil, cikloalkil, amino, alkilamino, dialkilamino, ili fenil; ili R8 je pirolidinil, piperidinil, piperazinil, N-alkilpiperazinil, homomorfolinil, homopiperidinil, morfolinil, ili tiomorfolinil; R9 je pirolidinil, piperidinil, piperazinil, N-alkilpiperazinil, homomorfolinil, homopiperidinil, morfolinil, ili tiomorfolinil; i (a) je jednostruka ili dvostruka veza, (b) je jednostruka ili dvostruka veza, uz uvjet da barem jedan od (a) i (b) bude jednostruka veza; ili farmaceutski prihvatljiva sol tog spoja. Patent sadrzi jos 9 patentnih zahtjeva.
Claims (10)
1. Spoj formule I
[image]
naznačen time što:
R1 je CO2R5 ili CONR6R7;
R2 je furanil, pirolil, tienil, pirazolil, oksazolil, tiazolil, izoksazolil, izotiazolil, oksadiazolil, triazolil, ili tetrazolil, i supstituiran je s 0-2 supstituenta izabranih između okso, amino, alkilamino, dialkilamino, alkil, (cikloalkil)alkil, hidroksialkil, (tetrahidrofuranil)alkil, (tetrahidropiranil)alkil, (CO2R5)alkil, (CON(R5)2)alkil, (COR9)alkil, (alkilsulfonil)alkil, i ((R9)alkil)CON(R5);
R3 je C5-7cikloalkil;
R4 je vodik, halo, hidroksi, alkil, ili alkoksi;
R5 je vodik, alkil, ili cikloalkil;
R6 je vodik, alkil, cikloalkil, alkoksi, ili SO2R8;
R7 je vodik , alkil, ili cikloalkil;
ili NR6R7 uzeti zajedno su pirolidinil, piperidinil, piperazinil, N-alkilpiperazinil, homomorfolinil, homopiperidinil, morfolinil, ili tiomorfolinil;
R8 je alkil, haloalkil, cikloalkil, amino, alkilamino, dialkilamino, ili fenil;
ili R8 je pirolidinil, piperidinil, piperazinil, N-alkilpiperazinil, homomorfolinil, homopiperidinil, morfolinil, ili tiomorfolinil;
R9 je pirolidinil, piperidinil, piperazinil, N-alkilpiperazinil, homomorfolinil, homopiperidinil, morfolinil, ili tiomorfolinil; i
(a) je jednostruka ili dvostruka veza, (b) je jednostruka ili dvostruka veza, uz uvjet da barem jedan od (a) i (b) bude jednostruka veza;
ili farmaceutski prihvatljiva sol tog spoja.
2. Spoj prema zahtjevu 1, naznačen time što R1 je CONR6R7; R6 je SO2R8; i R7 je vodik .
3. Spoj prema zahtjevu 1, naznačen time što R3 je cikloheksil.
4. Spoj prema zahtjevu 1, naznačen time što R4 je vodik.
5. Spoj prema zahtjevu 1, naznačen time što R4 je metoksi.
6. Spoj prema zahtjevu 1, naznačen time što se izabire iz skupine koja obuhvaća
13-cikloheksil-6-(1H-tetrazol-5-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-(2-etil-2H-tetrazol-5-il)-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-(2-etil-2H-tetrazol-5-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6-[2-etil]-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-6-[2-(2-hidroksietil)-1H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[2-(ciklopropilmetil)-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
i 13-cikloheksil-6-[2-(ciklopropilmetil)-2H-tetrazol-5-il]-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[2-[(tetrahidro-2-furanil)metil]-2H-tetrazol-5-il]-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[2-[(tetrahidro-2-furanil)metil]-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[1-[(tetrahidro-2-furanil)metil]-1H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[2-[(tetrahidro-2H-piran-4-il)metil]-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[2-[(tetrahidro-2H-piran-4-il)metil]-2H-tetrazol-5-il]-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[1-[(tetrahidro-2H-piran-4-il)metil]-1H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[1-[(tetrahidro-2H-piran-4-il)metil]-1H-tetrazol-5-il]-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6-[2-[(tetrahidro-2H-piran-4-il)metil]-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-3-metoksi-6-[2-[(tetrahidro-2H-piran-4-il)metil]-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-3-metoksi-6-[2-[(tetrahidro-2H-piran-4-il)metil]-2H-tetrazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-6-(4,5-dihidro-5-okso-1,3,4-oksadiazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-(4,5-dihidro-5-okso-1,3,4-oksadiazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[4,5-dihidro-5-okso-4-[(tetrahidro-2H-piran-4-il)metil]-1,3,4-oksadiazol-2-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[4,5-dihidro-5-okso-4-[(tetrahidro-2H-piran-4-il)metil]-1,3,4-oksadiazol-2-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[3-[(tetrahidro-2H-piran-4-il)metil]-1H-1,2,4-triazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-(3-metil-1,2,4-oksadiazol-5-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-(3-metil-1,2,4-oksadiazol-5-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6-(3-metil-1,2,4-oksadiazol-5-il)-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-6-[3-[(metilsulfonil)metil]-1,2,4-oksadiazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[3-[(metilsulfonil)metil]-1,2,4-oksadiazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6-[3-[(metilsulfonil)metil]-1,2,4-oksadiazol-5-il]-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
6-(5-amino-1,3,4-oksadiazol-2-il)-13-cikloheksil-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
6-(5-amino-1,3,4-oksadiazol-2-il)-13-cikloheksil-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
6-[5-[(bromoacetil)amino]-1,3,4-oksadiazol-2-il]-13-cikloheksil-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[5-[(4-morfolinilacetil)amino]-1,3,4-oksadiazol-2-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[5-[(4-morfolinilacetil)amino]-1,3,4-oksadiazol-2-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-6-[5-(3-metoksi-3-oksopropil)-2-oksazolil]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[5-[3-(4-morfolinil)-3-oksopropil]-2-oksazolil]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[5-[3-(4-morfolinil)-3-oksopropil]-2-oksazolil]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6-[5-[3-(4-morfolinil)-3-oksopropil]-2-oksazolil]-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6,7-dihidro-6-[5-[3-(4-morfolinil)-3-oksopropil]-2-oksazolil]-5H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-6-[5-[(tetrahidro-2H-piran-4-il)metil]-1,3,4-oksadiazol-2-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[5-[(tetrahidro-2H-piran-4-il)metil]-1H-1,2,4-triazol-3-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[1-metil-5-[(tetrahidro-2H-piran-4-il)metil]-1H-1,2,4-triazol-3-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina, metilni ester;
13-cikloheksil-6-[1-metil-5-[(tetrahidro-2H-piran-4-il)metil]-1H-1,2,4-triazol-3-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-cikloheksil-N-[(dimetilamino)sulfonil]-6-[1-metil-5-[(tetrahidro-2H-piran-4-il)metil]-1H-1,2,4-triazol-3-il]-7H-indol[2,1-a][2]benzazepin-10-karboksamid;
13-cikloheksil-6-[5-[(tetrahidro-2H-piran-4-il)metil]-1,3,4-oksadiazol-2-il]-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-Cikloheksil-6-(furan-3-il)-7H-indol{2,1-a][2]benzazepin-10-karboksilna kiselina;
Metil 13-cikloheksil-3-metoksi-6-(5-(3-metoksi-3-oksopropil)-1,3-oksazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilat;
3-(2-(13-Cikloheksil-3-metoksi-10-(metoksikarbonil)-7H-indol[2,1-a][2]benzazepin-6-il)-1,3-oksazol-5-il)propionska kiselina;
Metil 13-cikloheksil-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilat;
Metil 13-cikloheksil-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-6,7-dihidro-5H-indol[2,1-a][2]benzazepin-10-karboksilat;
13-Cikloheksil-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-6,7-dihidro-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-Cikloheksil-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-6,7-dihidro-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina. (vrh1- Kiralni izomer A);
13-Cikloheksil-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-6,7-dihidro-5H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina (vrh2- Kiralni izomer B);
13-Cikloheksil-N-((dimetilamino)sulfonil)-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-6,7-dihidro-5H-indol[2,1-a][2]benzazepin-10-karboksamid (Izomer B);
13-cikloheksil-N-((dimetilamino)sulfonil)-3-metoksi-6-(5-(3-(4-morfolinil)-3-oksopropil)-1,3-oksazol-2-il)-6,7-dihidro-5H-indol[2,1-a][2]benzazepin-10-karboksamid (Izomer A);
Metil 13-cikloheksil-3-metoksi-6-(1,3-oksazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilat;
13-Cikloheksil-3-metoksi-6-(1,3-oksazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksilna kiselina;
13-Cikloheksil-N-((dimetilamino)sulfonil)-3-metoksi-6-(1,3-oksazol-2-il)-7H-indol[2,1-a][2]benzazepin-10-karboksamid; i
13- Cikloheksil- N-((dimetilamino) sulfonil)- 3-metoksi-6-(1,3- oksazol- 2- il)- 6,7- dihidro-5H-indol [2,1- a] [2]benzazepin-10-karboksamid;
ili njegova farmaceutski prihvatljiva sol.
7. Smjesa, naznačena time što sadrži spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
8. Smjesa prema zahtjevu 7, naznačena time što dalje sadrži barem jedan dodatni spoj s terapijskim učinkom na virus hepatitisa C (HCV) pri čemu se taj spoj izabire iz skupine koja obuhvaća interferone, ciklosporine, interleukine, inhibitore metaloproteaze HCV-a, inhibitore serin proteaze HCV-a, inhibitore polimeraze HCV-a, inhibitore helikaze HCV-a, inhibitore proteina NS4B HCV-a, inhibitore ulaska HCV-a, inhibitore nakupljanja HCV-a, inhibitore izlaska HCV-a, inhibitore proteina NS5A HCV-a, inhibitore proteina NS5B HCV-a i inhibitore replikacije HCV-a.
9. Smjesa prema bilo kojem od zahtjeva 1 do 6, naznačen time što se koristi za liječenje zaraza virusom hepatitisa C.
10. Smjesa prema zahtjevu 9, naznačena time što se koristi za liječenje zaraza virusom hepatitisa C i dalje sadrži barem jedan dodatni spoj s terapijskim učinkom na HCV pri čemu se taj spoj izabire iz skupine koja obuhvaća interferone, ciklosporine, interleukine, inhibitore metaloproteaze HCV-a, inhibitore serin proteaze HCV-a, inhibitore polimeraze HCV-a, inhibitore helikaze HCV-a, inhibitore proteina NS4B HCV-a, inhibitore ulaska HCV-a, inhibitore nakupljanja HCV-a, inhibitore izlaska HCV-a, inhibitore proteina NS5A HCV-a, inhibitore proteina NS5B HCV-a i inhibitore replikacije HCV-a
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77139106P | 2006-02-08 | 2006-02-08 | |
| PCT/US2007/061768 WO2007092888A2 (en) | 2006-02-08 | 2007-02-07 | Hcv ns5b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100672T1 true HRP20100672T1 (hr) | 2011-01-31 |
Family
ID=38234480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100672T HRP20100672T1 (hr) | 2006-02-08 | 2010-12-06 | Hcv ns5b inhibitori |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7456165B2 (hr) |
| EP (1) | EP1987038B1 (hr) |
| JP (1) | JP5147731B2 (hr) |
| KR (1) | KR20080102161A (hr) |
| CN (1) | CN101379066B (hr) |
| AT (1) | ATE483712T1 (hr) |
| AU (1) | AU2007211988B2 (hr) |
| CY (1) | CY1111423T1 (hr) |
| DE (1) | DE602007009646D1 (hr) |
| DK (1) | DK1987038T3 (hr) |
| ES (1) | ES2352574T3 (hr) |
| HR (1) | HRP20100672T1 (hr) |
| NO (1) | NO20083513L (hr) |
| PL (1) | PL1987038T3 (hr) |
| PT (1) | PT1987038E (hr) |
| SI (1) | SI1987038T1 (hr) |
| WO (1) | WO2007092888A2 (hr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| WO2007140200A2 (en) * | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| US7456167B2 (en) * | 2006-05-25 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| JP2011515486A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の治療用化合物 |
| CN101981038B (zh) * | 2008-03-27 | 2013-07-10 | 百时美施贵宝公司 | 二氧戊环和二氧戊环酮稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂 |
| ES2416062T3 (es) * | 2008-03-27 | 2013-07-30 | Bristol-Myers Squibb Company | Inhibidores de NS5B del VHC de indolobenzadiazepina condensados con pirrolidina |
| CN101980711B (zh) | 2008-03-27 | 2012-10-31 | 百时美施贵宝公司 | 芳族杂环稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂 |
| US8133884B2 (en) | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| MX2011007195A (es) | 2009-01-07 | 2013-07-12 | Scynexis Inc | Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih). |
| CN102388045A (zh) * | 2009-02-11 | 2012-03-21 | 百时美施贵宝公司 | 用于治疗丙型肝炎的化合物 |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
| US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
| US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| BR112013016480A2 (pt) | 2010-12-30 | 2016-09-20 | Abbvie Inc | macrocíclo da fenantridina inibadores da protease da serina da hepatite c |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CN102276531A (zh) * | 2011-05-30 | 2011-12-14 | 扬子江药业集团广州海瑞药业有限公司 | 一种甲磺酸非诺多泮的制备方法 |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| CN104447952A (zh) * | 2014-12-11 | 2015-03-25 | 上海唐润医药科技有限公司 | 丙肝病毒蛋白酶抑制剂及其合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040138109A1 (en) * | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
| AU2004230946A1 (en) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US20050119318A1 (en) * | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
| RS50815B (sr) | 2004-02-24 | 2010-08-31 | Japan Tobacco Inc. | Kondenzovana heterotetraciklična jedinjenja i njihova upotreba kao inhibitora hcv polimeraza |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| ATE384723T1 (de) | 2004-10-13 | 2008-02-15 | Merck Patent Gmbh | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
| AU2005298412B2 (en) | 2004-10-26 | 2011-06-09 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
-
2007
- 2007-02-06 US US11/671,753 patent/US7456165B2/en active Active
- 2007-02-07 SI SI200730453T patent/SI1987038T1/sl unknown
- 2007-02-07 EP EP07763294A patent/EP1987038B1/en active Active
- 2007-02-07 AU AU2007211988A patent/AU2007211988B2/en not_active Ceased
- 2007-02-07 AT AT07763294T patent/ATE483712T1/de active
- 2007-02-07 DK DK07763294.1T patent/DK1987038T3/da active
- 2007-02-07 KR KR1020087021812A patent/KR20080102161A/ko not_active Application Discontinuation
- 2007-02-07 DE DE602007009646T patent/DE602007009646D1/de active Active
- 2007-02-07 JP JP2008554485A patent/JP5147731B2/ja not_active Expired - Fee Related
- 2007-02-07 ES ES07763294T patent/ES2352574T3/es active Active
- 2007-02-07 PL PL07763294T patent/PL1987038T3/pl unknown
- 2007-02-07 WO PCT/US2007/061768 patent/WO2007092888A2/en active Application Filing
- 2007-02-07 PT PT07763294T patent/PT1987038E/pt unknown
- 2007-02-07 CN CN2007800049834A patent/CN101379066B/zh not_active Expired - Fee Related
-
2008
- 2008-08-13 NO NO20083513A patent/NO20083513L/no not_active Application Discontinuation
-
2010
- 2010-12-06 HR HR20100672T patent/HRP20100672T1/hr unknown
-
2011
- 2011-01-04 CY CY20111100016T patent/CY1111423T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1987038T1 (sl) | 2011-02-28 |
| US20070185083A1 (en) | 2007-08-09 |
| CN101379066B (zh) | 2011-08-03 |
| ES2352574T3 (es) | 2011-02-21 |
| NO20083513L (no) | 2008-10-14 |
| PT1987038E (pt) | 2010-12-09 |
| CN101379066A (zh) | 2009-03-04 |
| US7456165B2 (en) | 2008-11-25 |
| PL1987038T3 (pl) | 2011-03-31 |
| EP1987038A2 (en) | 2008-11-05 |
| AU2007211988B2 (en) | 2012-02-02 |
| WO2007092888A2 (en) | 2007-08-16 |
| ATE483712T1 (de) | 2010-10-15 |
| CY1111423T1 (el) | 2015-08-05 |
| KR20080102161A (ko) | 2008-11-24 |
| AU2007211988A1 (en) | 2007-08-16 |
| DK1987038T3 (da) | 2011-01-31 |
| EP1987038B1 (en) | 2010-10-06 |
| JP2009526081A (ja) | 2009-07-16 |
| WO2007092888A3 (en) | 2007-10-11 |
| DE602007009646D1 (de) | 2010-11-18 |
| JP5147731B2 (ja) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100672T1 (hr) | Hcv ns5b inhibitori | |
| JP2009526081A5 (hr) | ||
| AU2017260125B2 (en) | Aromatic sulfonamide derivatives | |
| AU2018217860B2 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| AR063213A1 (es) | Amidas azociclicas fungicidas, composiciones fungicidas que las comprenden y su empleo en un metodo para controlar enfermedades en las plantas causadas por patogenos fungicos de la clase de los oomycetes. | |
| ES2374943T3 (es) | Inhibidores de serina proteasas | |
| AU2020204571A1 (en) | Pyrazole derivatives as sGC stimulators | |
| JP5805763B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| ES2449540T3 (es) | Inhibidores macrocíclicos del virus de la hepatitis C | |
| JP2010521483A5 (hr) | ||
| JP6082747B2 (ja) | フラグメント｛２−［４−（ビフェニル−４−イル）−１ｈ−イミダゾ−２−イル］ピロリジン−１−カルボニルメチル｝アミンを含む棒状ｃ型肝炎ウイルス阻害剤 | |
| CN102869657A (zh) | 用于治疗或预防黄病毒感染的类似物 | |
| JP2011523651A5 (hr) | ||
| JP6500010B2 (ja) | 新規ピリジン誘導体 | |
| JP2010510234A5 (hr) | ||
| CN102015727A (zh) | 丝氨酸蛋白酶的抑制剂 | |
| JP2011521965A5 (hr) | ||
| JP2014520822A5 (hr) | ||
| JP2013533317A5 (hr) | ||
| JP2008504281A5 (hr) | ||
| AR070361A1 (es) | Compuestos heterociclicos antiviricos | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| CN101648944A (zh) | 病毒聚合酶抑制剂 | |
| WO2014014874A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
| EP2410841A1 (en) | Substituted bicyclic hcv inhibitors |